HL-60 nuclear extract: sc-2147

The HL-60 nuclear extract is derived from the HL-60 cell line, a human promyelocytic leukemia cell line extensively used in hematological research. The cell line was originally established from a patient with acute promyelocytic leukemia and is characterized by its ability to differentiate into various types of myeloid cells under specific conditions. This versatility makes the HL-60 cell line, and by extension its nuclear extract, a valuable tool for studying the processes of cell differentiation and proliferation. The nuclear extract itself contains a complex mixture of nuclear proteins, including transcription factors, signaling molecules, and chromatin-associated proteins. These components are pivotal for understanding the regulation of gene expression during the differentiation and proliferation of white blood cells. In research, the HL-60 nuclear extract has been used to investigate the molecular mechanisms underlying hematopoiesis, the impact of genetic and environmental factors on leukemic cells, and the nuclear signaling pathways that govern cell cycle and growth. By analyzing this extract, scientists can explore the cellular transitions from a leukemic state to a differentiated state, providing insights into the cellular and molecular bases of leukemia and normal myeloid development.

HL-60 nuclear extract References:

1. Pyrrolo-1,5-benzoxazepines induce apoptosis in HL-60, Jurkat, and Hut-78 cells: a new class of apoptotic agents.  |  Zisterer, DM., et al. 2000. J Pharmacol Exp Ther. 293: 48-59. PMID: 10734152
2. ATRA-regulated Asb-2 gene induced in differentiation of HL-60 leukemia cells.  |  Kohroki, J., et al. 2001. FEBS Lett. 505: 223-8. PMID: 11566180
3. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFalpha is mediated via induction of NF-kappaB.  |  Prösch, S., et al. 1995. Virology. 208: 197-206. PMID: 11831701
4. Sp1 and Sp3 are involved in up-regulation of human deoxyribonuclease II transcription during differentiation of HL-60 cells.  |  Chou, SF., et al. 2003. Eur J Biochem. 270: 1855-62. PMID: 12694199
5. Brusatol-induced HL-60 cell differentiation involves NF-kappaB activation.  |  Cuendet, M., et al. 2004. Cancer Lett. 206: 43-50. PMID: 15019158
6. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.  |  Harker, WG., et al. 1991. Biochemistry. 30: 9953-61. PMID: 1655025
7. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.  |  Zwelling, LA., et al. 1990. Cancer Res. 50: 7116-22. PMID: 2171756
8. Increased expression and DNA-binding activity of transcription factor Sp1 in doxorubicin-resistant HL-60 leukemia cells.  |  Borellini, F., et al. 1990. Mol Cell Biol. 10: 5541-7. PMID: 2204818
9. Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells.  |  Jing, Y., et al. 1994. Jpn J Cancer Res. 85: 645-51. PMID: 8063619
10. Differences in expression of transcription factor AP-1 in human promyelocytic HL-60 cells during differentiation towards macrophages versus granulocytes.  |  Mollinedo, F., et al. 1993. Biochem J. 294 (Pt 1): 137-44. PMID: 8363564
11. Appearance of nuclear factors that interact with genes for myeloid calcium binding proteins (MRP-8 and MRP-14) in differentiated HL-60 cells.  |  Kuwayama, A., et al. 1993. Blood. 81: 3116-21. PMID: 8499645
12. Induction of the differentiation of HL-60 promyelocytic leukemia cells by curcumin in combination with low levels of vitamin D3.  |  Sokoloski, JA., et al. 1997. Oncol Res. 9: 31-9. PMID: 9112258
13. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB.  |  Sokoloski, JA., et al. 1997. Leukemia. 11: 1546-53. PMID: 9305611